# US 2010/0168191 A1 · Pharmaceutical formulation comprising pramipexole

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168191 A1
- Document ID: US20100168191A1
- Status: Published application
- Kind: A1
- Application number: 12/601,403
- Filed: 2008-05-10
- Published: 2010-07-01
- Earliest claimed: 2007-05-25
- Assignees: Boehringer Ingelheim International GmbH
- Inventors: Juergen Reess; Thomas Friedl; Nantharat Pearnchob
- Web page: https://patentgrep.com/patent/US20100168191A1

## CPC

- A61K 31/428: condensed with carbocyclic rings
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention refers to the use of a medicament for the paediatric treatment of RLS and/or Tic Disorder and/or Tourette's Syndrom.

## Claims

### Claim 1

A method for treating RLS in a child, comprising administering to a child suffering from RLS a per day dosage of pramipexole dihydrochloride monohydrate between 0.01 mg and 0.75 mg.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the per day dosage of pramipexole dihydrochloride monohydrate is between 0.01 mg and 0.5 mg.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

A method according to claim 1, wherein the pramipexole dihydrochloride monohydrate as active ingredient is contained in a pharmaceutical formulation further comprising mannitol, corn starch, colloidal silicon dioxide, povidone, and magnesium stearate.

### Claim 8 (depends on 7)

A method according to claim 7, wherein the pharmaceutical formulation is a tablet comprising pramipexole dihydrochloride monohydrate as active ingredient, mannitol, corn starch, colloidal silicon dioxide, povidone, and magnesium stearate, which tablet is contained in a package for the tablet and the package further includes a leaflet indicating that the intended patient group are children.

### Claim 9

A method for treating RLS in a child, comprising administering to a child suffering from RLS a pharmaceutical formulation comprising pramipexole free base or a pramipexole salt form in an amount that corresponds to 0.06 mg to 0.09 mg of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 9)

A method according to claim 9, wherein the pramipexole free base or pramipexole salt form is present in an amount that corresponds to 0.088 mg of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole.

### Claim 14

A method for treating RLS in a child, comprising administering to a child suffering from RLS a pharmaceutical formulation comprising pramipexole free base or a pramipexole salt form in an amount that corresponds to 0.03 mg to 0.05 mg of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the pramipexole free base or pramipexole salt form is present in an amount that corresponds to 0.044 mg of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole.

### Claim 16

A method for treating RLS in a child, comprising administering to a child suffering from RLS a pharmaceutical formulation comprising pramipexole free base or a pramipexole salt form in an amount that corresponds to 0.01 mg to 0.029 mg of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole.

### Claim 17 (depends on 16)

A method according to claim 16, wherein the pramipexole free base or pramipexole salt form is present in an amount that corresponds to 0.022 mg of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole.
